SI-BONE (NASDAQ:SIBN) Posts Earnings Results, Beats Expectations By $0.05 EPS

SI-BONE (NASDAQ:SIBN) released its quarterly earnings data on Monday. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.05, Zacks reports. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. SI-BONE updated its FY 2025 guidance to EPS.

SI-BONE Stock Performance

SI-BONE stock traded down $0.37 during trading on Monday, reaching $17.47. The company had a trading volume of 481,703 shares, compared to its average volume of 337,872. The firm has a market capitalization of $732.66 million, a price-to-earnings ratio of -18.99 and a beta of 1.17. The company has a current ratio of 8.25, a quick ratio of 7.22 and a debt-to-equity ratio of 0.22. The firm’s 50-day simple moving average is $15.65 and its 200 day simple moving average is $14.66. SI-BONE has a 52 week low of $11.70 and a 52 week high of $20.60.

Insider Buying and Selling at SI-BONE

In other SI-BONE news, insider Anthony J. Recupero sold 3,670 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $13.90, for a total value of $51,013.00. Following the completion of the transaction, the insider now directly owns 222,814 shares in the company, valued at $3,097,114.60. This represents a 1.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Anshul Maheshwari sold 5,304 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $13.91, for a total transaction of $73,778.64. Following the completion of the sale, the chief financial officer now directly owns 189,319 shares of the company’s stock, valued at approximately $2,633,427.29. This trade represents a 2.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 9,311 shares of company stock valued at $130,356. Company insiders own 3.90% of the company’s stock.

Analysts Set New Price Targets

SIBN has been the subject of a number of research reports. Truist Financial boosted their target price on shares of SI-BONE from $16.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Needham & Company LLC reissued a “buy” rating and issued a $19.00 target price on shares of SI-BONE in a research report on Monday, January 13th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, SI-BONE has a consensus rating of “Buy” and a consensus price target of $23.00.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.